- Home
- AMS vs XTLB Comparison
AMS vs XTLB Comparison
Compare AMS & XTLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- XTLB
- Stock Information
- Founded
- AMS 1980
- XTLB 1993
- Country
- AMS United States
- XTLB Israel
- Employees
- AMS N/A
- XTLB N/A
- Industry
- AMS Medical Specialities
- XTLB Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- XTLB Health Care
- Exchange
- AMS Nasdaq
- XTLB Nasdaq
- Market Cap
- AMS 19.3M
- XTLB 16.3M
- IPO Year
- AMS N/A
- XTLB 2005
- Fundamental
- Price
- AMS $2.78
- XTLB $1.21
- Analyst Decision
- AMS
- XTLB
- Analyst Count
- AMS 0
- XTLB 0
- Target Price
- AMS N/A
- XTLB N/A
- AVG Volume (30 Days)
- AMS 28.0K
- XTLB 6.6K
- Earning Date
- AMS 03-26-2025
- XTLB 03-25-2025
- Dividend Yield
- AMS N/A
- XTLB N/A
- EPS Growth
- AMS 779.12
- XTLB N/A
- EPS
- AMS 0.61
- XTLB N/A
- Revenue
- AMS $24,969,000.00
- XTLB $46,000.00
- Revenue This Year
- AMS $27.74
- XTLB N/A
- Revenue Next Year
- AMS $17.72
- XTLB N/A
- P/E Ratio
- AMS $4.46
- XTLB N/A
- Revenue Growth
- AMS 20.83
- XTLB N/A
- 52 Week Low
- AMS $2.51
- XTLB $0.85
- 52 Week High
- AMS $4.60
- XTLB $4.99
- Technical
- Relative Strength Index (RSI)
- AMS 36.67
- XTLB 36.47
- Support Level
- AMS $2.85
- XTLB $1.19
- Resistance Level
- AMS $3.10
- XTLB $1.38
- Average True Range (ATR)
- AMS 0.10
- XTLB 0.12
- MACD
- AMS -0.01
- XTLB -0.01
- Stochastic Oscillator
- AMS 32.50
- XTLB 8.11
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About XTLB XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.